In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Prometheus gets US Lotronex rights from GSK

Executive Summary

Prometheus (therapeutics and diagnostics for gastrointestinal, autoimmune, and inflammatory diseases) has licensed exclusive US marketing rights to GlaxoSmithKline's controversial irritable bowel syndrome drug Lotronex (alosetron).
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Marketing-Licensing
    • Reverse Licensing
    • Includes Equity

Related Companies